Literature DB >> 32950039

The protective effect of O blood type against SARS-CoV-2 infection.

Massimo Franchini1, Claudia Glingani1, Claudia Del Fante2, Martina Capuzzo3, Vincenza Di Stasi4, Giulia Rastrelli4, Linda Vignozzi4, Giuseppe De Donno5, Cesare Perotti2.   

Abstract

Entities:  

Keywords:  ABO blood group; COVID-19; SARS-CoV-2

Year:  2020        PMID: 32950039      PMCID: PMC7537255          DOI: 10.1111/vox.13003

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.996


× No keyword cloud information.
ABO antigens, which are ubiquitously expressed on the surface of human cells and tissues, have been implied in a wide array of diseases, first of all cardiovascular disorders [1, 2]. Recent evidence has suggested a relationship between the ABO blood group and the susceptibility of developing severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) [3, 4]. In particular, it has been hypothesized that individuals belonging to O blood type are less susceptible to SARS‐CoV‐2 infection than those belonging to non‐O blood groups [4]. The reason for this phenomenon could reside in the presence in O blood group subjects of IgG anti‐A isoagglutinins which would prevent the binding of SARS‐CoV‐2 to its receptor thereby inhibiting the virus entry into the targeted human cells [5]. To verify the protective effect of O blood type against SARS‐CoV‐2 infection, we have compared the ABO blood group distribution of all donors of convalescent plasma (CP) with that of healthy uninfected periodic volunteer blood donors. During the period between 25 March 2020 and 22 June 2020, 447 consecutive CP donors were enrolled at the University Hospital of Pavia and the City Hospital of Mantova, Lombardy region, Italy. All CP donors were of Caucasian origin and were recovered (clinical resolution of symptoms from at least 14 days with two consecutive negative SARS‐CoV‐2 RT‐PCR nasal swabs) from coronavirus disease 2019 (COVID‐19). These subjects were compared with an historical series of 16 911 healthy blood donors from the same geographical area (Table 1, upper section). The two analytical population were comparable in terms of age, whereas as expected an extra representation of males was observed in CP donors. Indeed, in accordance with the Italian transfusion law for the prevention of transfusion‐related acute lung injury (TRALI), only nulliparous women can donate CP. The prevalence of O blood type in CP donors was significantly lower than that observed in healthy blood donors of Mantua and Pavia (Table 1). According to these data, the relative risk (and 95% confidence interval) of having experienced SARS‐CoV‐2 infection in O blood type subjects is estimated as 0·74 (0·6–0·90), thus suggesting the protective role of O blood type towards SARS‐CoV‐2 contraction. When considering in CP donors the clinical course of the disease, O blood type did not appear as a modulator of the severity of COVID‐19 (Table 1 bottom section). Interestingly, considering O and B blood groups together and comparing them with the other blood types, the O blood type‐related protective effect disappeared (Table 1). This finding could be in contrast with the hypothesized anti‐SARS‐CoV‐2 activity of anti‐A isoagglutinins, which are present also in B group individuals. However, the neutralizing effect could be a characteristic of anti‐A isoagglutinins belonging to IgG class (predominant in O blood type individuals) and not of those belonging to IgM class (predominant in B blood group subjects).
Table 1

Comparison of characteristics of observed samples.

CharacteristicsCP donorsHealthy blood donors P value b
Number44716 911
Mean age (y, ±SD)47·7±12·147·1 ±14·30·41
N Males/Females385/6210 321/6590
%Males86·161·0<0·0001
ABO blood group
O162 (36·2%)7,375 (43·6%)0·002 c , d
Non‐O285 (63·8%)9,536 (56·4%)
A207 (46·3%)7,209 (42·6%)
B54 (12·1%)1,620 (9·6%)
AB24 (5·4%)707 (4·2%)

CP, convalescent plasma; SD, standard deviation; y, years.

Patients with SARS‐CoV‐2 pneumonia requiring hospitalization with mechanical (invasive or not invasive) respiratory support. All the other cases were classified as non‐severe.

CP donors vs. healthy blood donors.

O blood type versus non‐O blood type.

O and B blood types versus other blood types: P = 0·06.

Comparison of characteristics of observed samples. CP, convalescent plasma; SD, standard deviation; y, years. Patients with SARS‐CoV‐2 pneumonia requiring hospitalization with mechanical (invasive or not invasive) respiratory support. All the other cases were classified as non‐severe. CP donors vs. healthy blood donors. O blood type versus non‐O blood type. O and B blood types versus other blood types: P = 0·06. In conclusion, we documented for the first time the association between ABO blood type and COVID‐19 in a homogeneous population of CP donors recovered from SARS‐CoV‐2 infection, having O blood type subjects a reduced predisposition to become infected.

Conflict of interest

The authors declare no conflict of interests.
  5 in total

Review 1.  ABO blood group and thrombotic vascular disease.

Authors:  M Franchini; P M Mannucci
Journal:  Thromb Haemost       Date:  2014-09-04       Impact factor: 5.249

Review 2.  The relationship between blood groups and disease.

Authors:  David J Anstee
Journal:  Blood       Date:  2010-03-22       Impact factor: 22.113

3.  COVID-19 and ABO blood groups.

Authors:  Sunny Dzik; Kent Eliason; Edward B Morris; Richard M Kaufman; Crystal M North
Journal:  Transfusion       Date:  2020-08-01       Impact factor: 3.337

4.  Association between ABO blood groups and risk of SARS-CoV-2 pneumonia.

Authors:  Juyi Li; Xiufang Wang; Jian Chen; Yi Cai; Aiping Deng; Ming Yang
Journal:  Br J Haematol       Date:  2020-05-26       Impact factor: 6.998

5.  Anti-A isohaemagglutinin titres and SARS-CoV-2 neutralization: implications for children and convalescent plasma selection.

Authors:  Daniele Focosi
Journal:  Br J Haematol       Date:  2020-07-08       Impact factor: 8.615

  5 in total
  10 in total

Review 1.  ABO blood group and COVID-19: an updated systematic literature review and meta-analysis.

Authors:  Massimo Franchini; Mario Cruciani; Carlo Mengoli; Giuseppe Marano; Fabio Candura; Nadia Lopez; Ilaria Pati; Simonetta Pupella; Vincenzo De Angelis
Journal:  Blood Transfus       Date:  2021-05-12       Impact factor: 3.443

2.  Relationship between ABO Blood Group Distribution and COVID-19 Infection in Patients Admitted to the ICU: A Multicenter Observational Spanish Study.

Authors:  Carlos Jericó; Saioa Zalba-Marcos; Manuel Quintana-Díaz; Olga López-Villar; Iván Santolalla-Arnedo; Ane Abad-Motos; María Jesús Laso-Morales; Esther Sancho; Maricel Subirà; Eva Bassas; Regina Ruiz de Viñaspre-Hernández; Raúl Juárez-Vela; José Antonio García-Erce
Journal:  J Clin Med       Date:  2022-05-28       Impact factor: 4.964

Review 3.  The Role of ABO Blood Type in Patients with SARS-CoV-2 Infection: A Systematic Review.

Authors:  Federico Banchelli; Pierpaolo Negro; Marcello Guido; Roberto D'Amico; Veronica Andrea Fittipaldo; Pierfrancesco Grima; Antonella Zizza
Journal:  J Clin Med       Date:  2022-05-27       Impact factor: 4.964

Review 4.  Convalescent Plasma for the Treatment of Severe COVID-19.

Authors:  Massimo Franchini; Giancarlo Maria Liumbruno
Journal:  Biologics       Date:  2021-02-04

Review 5.  ABO Blood Types and COVID-19: Spurious, Anecdotal, or Truly Important Relationships? A Reasoned Review of Available Data.

Authors:  Jacques Le Pendu; Adrien Breiman; Jézabel Rocher; Michel Dion; Nathalie Ruvoën-Clouet
Journal:  Viruses       Date:  2021-01-22       Impact factor: 5.048

6.  Low Levels of Natural Anti-α-N-Acetylgalactosamine (Tn) Antibodies Are Associated With COVID-19.

Authors:  Adrien Breiman; Nathalie Ruvoën-Clouet; Marie Deleers; Tiffany Beauvais; Nicolas Jouand; Jézabel Rocher; Nicolai Bovin; Nathalie Labarrière; Hanane El Kenz; Jacques Le Pendu
Journal:  Front Microbiol       Date:  2021-02-11       Impact factor: 5.640

Review 7.  The relationship between blood groups and risk of infection with SARS-CoV-2 or development of severe outcomes: A review.

Authors:  Pourya Shokri; Saeid Golmohammadi; Maryam Noori; Seyed Aria Nejadghaderi; Kristin Carson-Chahhoud; Saeid Safiri
Journal:  Rev Med Virol       Date:  2021-05-14       Impact factor: 11.043

8.  Correlation between ABO blood group and neutralizing anti-SARS-CoV-2 antibody titers in convalescent plasma donations.

Authors:  M Franchini; C Mengoli; A Ballotari; C Glingani
Journal:  Transfus Clin Biol       Date:  2021-10-12       Impact factor: 2.126

9.  Systematic review and meta-analysis of the effect of ABO blood group on the risk of SARS-CoV-2 infection.

Authors:  George Balaouras; Paolo Eusebi; Polychronis Kostoulas
Journal:  PLoS One       Date:  2022-07-28       Impact factor: 3.752

10.  Convalescent Plasma for Hospitalized COVID-19 Patients: A Single-Center Experience.

Authors:  Massimo Franchini; Claudia Glingani; Giuseppe De Donno; Giuseppe Lucchini; Massimiliano Beccaria; Massimo Amato; Gian Paolo Castelli; Leonardo Bianciardi; Mauro Pagani; Marco Ghirardini; Giuseppe Puma; Barbara Presciuttini; Maria Teresa Costantino; Marilena Frigato; Verena Crosato; Giorgio Tiecco; Alice Mulè; Dorothea Angela Papalia; Francesco Inglese; Fabio Spreafico; Martina Garuti; Antonietta Pecoriello; Giulia Cervi; Graziana Greco; Vanni Galavotti; Tiziana Santini; Angela Berselli; Carlo Montalto; Riccardo Bertoletti; Simona Aurelia Bellometti; Enrico Capuzzo; Dario Benazzi; Gianpaolo Grisolia; Fabio Pajola; Raffaello Stradoni; Matteo Zani; Adriano Verzola; Vito Codeluppi; Silvia Vesentini; Elisa Bellocchio; Marco Candini; Giorgina Ambrosi; Francesca Carandina; Cleante Scarduelli; Albino Reggiani; Salvatore Casari
Journal:  Life (Basel)       Date:  2022-03-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.